NVCR Stock Analysis: Novocure | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.656m USD | 12M Return: 11.2% | JE00BYSS4X48 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.2M
Qual. Beats: 1
Rev. Trend: 98.8%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NovoCure Limited (NASDAQ: NVCR) is a Switzerland-based oncology company that develops, manufactures, and commercializes Tumor Treating Fields (TTFields) devices for solid tumor cancers. Its product portfolio includes Optune Gio, Optune Lua, and Optune Pax, which are sold across the United States, Germany, France, Japan, Greater China, and other international markets. The company is also advancing multiple clinical trials evaluating TTFields in indications such as brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000 and headquartered in Baar, Switzerland, NovoCure operates within the Health Care Equipment sub-industry and listed on NASDAQ in 2015.
TTFields represents a non-invasive, device-based cancer treatment modality that delivers low-intensity alternating electric fields to disrupt cancer cell division, distinguishing NovoCure from traditional pharmaceutical-based oncology therapies. As a medical device manufacturer, the company generates revenue primarily through the prescription and sale of its wearable TTFields systems to patients and oncology treatment centers.
- Optune Gio revenue growth slows in U.S. glioblastoma market
- NSCLC trial failure clouds TTFields pipeline outlook
- Reimbursement coverage expansions accelerate European market penetration
| Net Income: -148.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 3.80 > 1.0 |
| NWC/Revenue: 59.76% < 20% (prev 52.95%; Δ 6.81% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.49m > Net Income -148.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (116.0m) vs 12m ago 3.98% < -2% |
| Gross Margin: 76.13% > 18% (prev 76.38%; Δ -0.26% > 0.5%) |
| Asset Turnover: 68.51% > 50% (prev 50.58%; Δ 17.93% > 0%) |
| Interest Coverage Ratio: -8.74 > 6 (EBIT TTM -149.0m / Interest Expense TTM 17.0m) |
| A: 0.53 (Total Current Assets 638.5m - Total Current Liabilities 220.7m) / Total Assets 795.2m |
| B: -1.73 (Retained Earnings -1.38b / Total Assets 795.2m) |
| C: -0.15 (EBIT TTM -149.0m / Avg Total Assets 1.02b) |
| D: 0.74 (Book Value of Equity 338.1m / Total Liabilities 457.1m) |
| Altman-Z'' = -2.40 = D |
| DSRI: 1.02 (Receivables 145.8m/129.1m, Revenue 699.2m/630.2m) |
| GMI: 1.00 (GM 76.38% / 76.13%) |
| AQI: 1.10 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.11 (Revenue 699.2m / 630.2m) |
| TATA: -0.19 (NI -148.6m - CFO 1.49m) / TA 795.2m) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of October 13, 2026, the stock is trading at USD 14.72 with a total of 781,979 shares traded. Over the past week, the price has changed by -3.16%, over one month by -9.25%, over three months by -8.51% and over the past year by +11.18%.
Current recommended Stop Loss: 13.80 (which is 6.2% or 1.3 ATR below the current price).
Novocure has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NVCR.
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.9 | 82.5% |
P/E Forward = 909.0909
P/S = 2.3682
P/B = 5.5986
P/EG = -0.47
Revenue TTM = 699.2m USD
EBIT TTM = -149.0m USD
EBITDA TTM = -132.6m USD
Long Term Debt = 195.9m USD (from longTermDebt, last quarter)
Short Term Debt = 11.7m USD (from shortTermDebt, last fiscal year)
Debt = 270.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 37.5m
Net Debt = -169.6m USD (calculated: Debt 270.9m - CCE 440.6m)
Enterprise Value = 1.49b USD (1.66b + Debt 270.9m - CCE 440.6m)
Interest Coverage Ratio = -8.74 (Ebit TTM -149.0m / Interest Expense TTM 17.0m)
EV/FCF = -70.36x (Enterprise Value 1.49b / FCF TTM -21.1m)
FCF Yield = -1.42% (FCF TTM -21.1m / Enterprise Value 1.49b)
FCF Margin = -3.02% (FCF TTM -21.1m / Revenue TTM 699.2m)
Net Margin = -21.25% (Net Income TTM -148.6m / Revenue TTM 699.2m)
Gross Margin = 76.13% ((Revenue TTM 699.2m - Cost of Revenue TTM 166.9m) / Revenue TTM)
Gross Margin QoQ = 77.61% (prev 77.63%)
Tobins Q-Ratio = 1.87 (Enterprise Value 1.49b / Total Assets 795.2m)
Interest Expense / Debt = 6.29% (Interest Expense 17.0m / Debt 270.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -117.7m (EBIT -149.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.89 (Total Current Assets 638.5m / Total Current Liabilities 220.7m)
Debt / Equity = 0.80 (Debt 270.9m / totalStockholderEquity, last quarter 338.1m)
Debt / EBITDA = 1.28 (negative EBITDA) (Net Debt -169.6m / EBITDA -132.6m)
Debt / FCF = 8.03 (negative FCF - burning cash) (Net Debt -169.6m / FCF TTM -21.1m)
Total Stockholder Equity = 337.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.56% (Net Income -148.6m / Total Assets 795.2m)
RoE = -44.00% (Net Income TTM -148.6m / Total Stockholder Equity 337.7m)
RoCE = -27.92% (EBIT -149.0m / Capital Employed (Equity 337.7m + L.T.Debt 195.9m))
RoIC = -21.35% (negative operating profit) (NOPAT -117.7m / Invested Capital 551.2m)
WACC = 11.01% (E(1.66b)/V(1.93b) * Re(12.0%) + D(270.9m)/V(1.93b) * Rd(6.29%) * (1-Tc(0.21)))
Discount Rate = 12.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.61 | Cagr: 3.55%
[DCF] Fair Price = unknown (Cash Flow -21.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.18 | # QB: 1
Revenue Correlation: 98.84 | Revenue CAGR: 12.99% | SUE: 2.27 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.23 | Chg30d=+4.08% | Revisions=+44% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.24 | Chg30d=+1.26% | Revisions=+67% | GrowthEPS=-1.2% | GrowthRev=+10.8%
EPS next Year (2027-12-31): EPS=-0.81 | Chg30d=+1.22% | Revisions=+44% | GrowthEPS=+34.7% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: +67% (up=16, down=2)